As there is no vaccine for COVID-19 yet doctors and researchers around the world are testing some of the existing drugs to treat the viral disease. One of the much-touted drugs is remdesivir the antiviral drug originally designed to treat Ebola. Some studies have suggested that remdesivir may decrease the time needed for clinical improvement in moderate to severe cases. Based on these studies the Drug Controller General of India (DCGI) has approved remdesivir for “restricted emergency use” on severely ill hospitalised coronavirus patients. Three pharma companies – Cipla Hetero and Mylan NV – have also been given approval by